Vaccines, therapeutics and translational nucleic acids
Our research aims to develop and utilise nucleic acid therapeutics for new and effective therapies targeting disease, but also to improve the efficiency of our manufacturing processes and analytical methods for characterisation.
Traditional drug discovery has focused on developing small molecules to treat disease. However, interest in therapeutics based on nucleic acids has increased rapidly, driven partly by the astounding success of mRNA based vaccines for COVID-19 and new gene therapy approaches.
Nucleic acids based therapeutics currently have a market value of >$40 billion, which is estimated to grow to over $100 billion by 2026. Nucleic acids-based approaches hold promise for treatments beyond vaccines and infectious diseases to treatments for cancer, metabolic disorders, cardiovascular conditions, and autoimmune diseases.
Our research aims to develop and utilise nucleic acid therapeutics for new and effective therapies targeting disease, but also to improve the efficiency of our manufacturing processes and analytical methods for characterisation.
This research theme is lead by Dr Zoltán Kis.
